NO20076595L - Behandling av leversykdommer hvor jern spiller en rolle i patogenesen - Google Patents

Behandling av leversykdommer hvor jern spiller en rolle i patogenesen

Info

Publication number
NO20076595L
NO20076595L NO20076595A NO20076595A NO20076595L NO 20076595 L NO20076595 L NO 20076595L NO 20076595 A NO20076595 A NO 20076595A NO 20076595 A NO20076595 A NO 20076595A NO 20076595 L NO20076595 L NO 20076595L
Authority
NO
Norway
Prior art keywords
treatment
pathogenesis
role
liver diseases
iron plays
Prior art date
Application number
NO20076595A
Other languages
English (en)
Norwegian (no)
Inventor
Daniele Alberti
Peter Marks
Hanspeter Nick
Lisa Grace Rojkjaer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20076595L publication Critical patent/NO20076595L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
NO20076595A 2005-05-31 2007-12-20 Behandling av leversykdommer hvor jern spiller en rolle i patogenesen NO20076595L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68584805P 2005-05-31 2005-05-31
US69280805P 2005-06-22 2005-06-22
US74678606P 2006-05-09 2006-05-09
PCT/US2006/020677 WO2006130532A2 (fr) 2005-05-31 2006-05-30 Traitement des maladies hepatiques dans la pathogenese desquelles le fer joue un role

Publications (1)

Publication Number Publication Date
NO20076595L true NO20076595L (no) 2007-12-20

Family

ID=37106984

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076595A NO20076595L (no) 2005-05-31 2007-12-20 Behandling av leversykdommer hvor jern spiller en rolle i patogenesen

Country Status (16)

Country Link
US (3) US20080199428A1 (fr)
EP (1) EP1893198A2 (fr)
JP (2) JP2008542380A (fr)
KR (2) KR20080003933A (fr)
AU (1) AU2006252718B2 (fr)
BR (1) BRPI0610873A2 (fr)
CA (1) CA2608709A1 (fr)
CR (1) CR9454A (fr)
EA (1) EA014772B1 (fr)
IL (1) IL187000A0 (fr)
MA (1) MA29542B1 (fr)
MX (1) MX2007015085A (fr)
NO (1) NO20076595L (fr)
SM (1) SMAP200700061A (fr)
TN (1) TNSN07447A1 (fr)
WO (1) WO2006130532A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
PL359169A1 (en) 2000-05-26 2004-08-23 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses
KR20050035194A (ko) 2002-06-28 2005-04-15 이데닉스 (케이만) 리미티드 플라비비리다에 감염 치료용 2'-c-메틸-3'-o-l-발린에스테르 리보푸라노실 사이티딘
CN101172993A (zh) 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2′-c-甲基-3′-o-l-缬氨酸酯核糖呋喃基胞苷
AU2003298658A1 (en) 2002-11-15 2004-06-15 Idenix (Cayman) Limited 2'-branched nucleosides and flaviviridae mutation
US7598373B2 (en) 2002-12-12 2009-10-06 Idenix Pharmaceuticals, Inc. Process for the production of 2-C-methyl-D-ribonolactone
RU2008109649A (ru) * 2005-08-15 2009-09-27 Ф.Хоффманн-Ля Рош Аг (Ch) ПЭГ-IFNα И РИБАВИРИН ДЛЯ ЛЕЧЕНИЯ ВИРУСА ГЕПАТИТА В
EP1927591A1 (fr) * 2006-11-29 2008-06-04 Novartis AG Formes polymorphes de deferasirox (ICL670)
CA2670313C (fr) 2006-11-29 2013-02-12 Novartis Ag Formes polymorphes de deferasirox (icl670a)
KR102198749B1 (ko) * 2011-03-02 2021-01-06 제롬 쉔타그 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如,与abt-072或abt-333)
DE112012003510T5 (de) 2011-10-21 2015-03-19 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
EA038594B1 (ru) * 2011-10-28 2021-09-21 Шайр Хьюман Дженетик Терапис, Инк. Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
CA2941411A1 (fr) * 2014-03-21 2015-09-24 Tobira Therapeutics, Inc. Cenicriviroc pour le traitement de la fibrose
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
GB202005054D0 (en) 2020-04-06 2020-05-20 Nemysis Ltd Carboxylate Ligand Modified Ferric Iron Hydroxide Compositions for Use in the Treatment or Prevention of Iron Deficiency Associated with Liver Diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY129541A (en) * 1996-06-25 2007-04-30 Novartis Ag Substituded 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
JP4125011B2 (ja) * 2002-01-22 2008-07-23 株式会社 伊藤園 過剰鉄起因肝障害予防・治療剤及び過剰鉄起因肝障害予防・治療飲食物

Also Published As

Publication number Publication date
KR20080003933A (ko) 2008-01-08
EA200702384A1 (ru) 2008-06-30
JP5869469B2 (ja) 2016-02-24
KR101174966B1 (ko) 2012-08-17
MX2007015085A (es) 2008-01-17
KR20100018057A (ko) 2010-02-16
TNSN07447A1 (en) 2009-03-17
US20080199428A1 (en) 2008-08-21
MA29542B1 (fr) 2008-06-02
WO2006130532A2 (fr) 2006-12-07
CA2608709A1 (fr) 2006-12-07
JP2013082726A (ja) 2013-05-09
AU2006252718A1 (en) 2006-12-07
CR9454A (es) 2008-04-16
US20130109730A1 (en) 2013-05-02
BRPI0610873A2 (pt) 2010-08-03
JP2008542380A (ja) 2008-11-27
WO2006130532A3 (fr) 2007-11-22
IL187000A0 (en) 2008-02-09
US20100098662A1 (en) 2010-04-22
SMAP200700061A (it) 2007-12-28
EA014772B1 (ru) 2011-02-28
EP1893198A2 (fr) 2008-03-05
AU2006252718B2 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
TNSN07447A1 (en) Treatment of liver diseases in which iron plays a role in pathogenesis
NO20080284L (no) Cannabionoid aktiv farmasoytisk ingrediens for forbedrede doseringsformer
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
MX2010004673A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos.
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
TW200736223A (en) N-(pyridin-2-yl)-sulfonamide derivatives
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
MX2009001660A (es) Compuestos de 2,5-dihidroxibenceno para el tratamiento de psoriasis.
WO2007128086A3 (fr) Nouvel inhibiteur de la réplication virale
NO20085271L (no) Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni
MA46268B1 (fr) Dérivés de 5-[2-(pyridin-2-ylamino)-1 ,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gamma
EP2796450A4 (fr) Dérivés 6-aminopyridine-3-ol ou leurs sels pharmaceutiquement acceptables, et composition pharmaceutique contenant ces dérivés ou ces sels comme principes actifs pour la prévention ou le traitement des maladies provoquées par l'angiogenèse
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
AR048336A1 (es) Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
EP2050442A4 (fr) Composition pharmaceutique destinée à la prévention et/ou au traitement d'une maladie osseuse, aliment fonctionnel ou aliment diététique contenant la composition, et préparation pharmaceutique contenant la composition en tant que principe actif
JP2006511538A5 (fr)
MA33563B1 (fr) 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl
JP2008540506A5 (fr)
NO20084913L (no) Sammensetning inneholdende en jernchelator og et anti-neoplatisk middel og anvendelse derav
UY30935A1 (es) Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones.
MA29922B1 (fr) NOUVEAUX DERIVES DE BENZIMIDAZOLES ET BENZOTHIAZOLES, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE CMet
EA201000701A1 (ru) 4-[4-(2-адамантилкарбамоил)-5-трет-бутилпиразол-1-ил]бензойная кислота-465
UY30126A1 (es) Una nueva sal farmaceuticamente aceptable de 2-hidroxi-3-(5-(morfolin-4-ilmetil)-piridin-2-l)1h-indol-5-carbonitrilo, procedimientos para su preparacion, composiciones que la contienen yaplicaciones
WO2006108682A3 (fr) Substances et compositions pharmaceutiques destinees a inhiber les glyoxalases, et leur utilisation comme agents antifongiques
NO20063858L (no) Antimikrobielle preservativer for oppnaelse av en multidoseformulering ved bruk av beta-cyklodekstriner for flytende doseringsformer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application